Can Annamycin bridge cytotoxic therapy and immunotherapy in pancreatic cancer?
Find out how Annamycin could bridge chemotherapy and immunotherapy in pancreatic cancer and what AACR 2026 data signals for future trials.
Moleculin Biotech, Inc. secures Japanese IP boost as Annamycin enters pivotal Phase 3
Moleculin secures Japanese patent for Annamycin reconstitution. Discover what this means for AML development and global market strategy.
How annamycin’s clean cardiac safety profile may strengthen Moleculin’s oncology development strategy
Independent reviewers found no cardiotoxicity for Moleculin’s annamycin in 90 subjects. See how this safety milestone may reshape its oncology development path.